Press Release February 26, 2022Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis 0 0 Share
Press Release February 26, 2022Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria 0 0 Share
Press Release February 26, 2022Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis 0 0 Share
Press Release February 26, 2022Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria 0 0 Share
Company Ticker News February 18, 2022Is Regeneron Pharmaceuticals (REGN) Stock a Suitable Value Pick? 0 0 Share
Company Ticker News February 18, 2022Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial 0 0 Share
Press Release February 18, 2022Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program 0 0 Share
Press Release February 18, 2022Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program 0 0 Share
Press Release February 11, 2022Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting 0 0 Share
